3 MedTech Stocks Poised to Gain in 2026 From the AI Boom

Porsche Consulting finds AI—particularly generative AI—is moving MedTech from promise to practice by accelerating R&D (generative design, virtual testing, faster trials and regulatory documentation), optimizing manufacturing and supply chains, and personalizing commercial and clinical workflows; the FDA has greenlit 209 AI-enabled devices in 2025 and radiology leads with 956 AI devices approved to date, while specialties such as interventional pulmonology and oncology show strong AI applicability. The report warns incumbents must shift from pilots to large-scale implementation to capture cost, quality and throughput gains across operations and care delivery, creating a strategic imperative for investors to prioritize companies with scalable AI platforms, proprietary data and sticky ecosystems. Zacks highlights three AI-exposed names: Stryker (SYK) for its Mako SmartRobotics ecosystem (2m+ procedures, Mako 4) with projected 2025 earnings growth of 11.2%, strong cashflow and ROE; Tempus (TEM) for its multimodal AI platform, recent FDA 510(k) clears, Paige acquisition and very high projected sales/earnings growth; and GE HealthCare (GEHC) for its NVIDIA partnership and advanced imaging products—each rated Zacks #3 (Hold) but flagged for AI-driven growth potential.

Analysis

Porsche Consulting reports that generative AI is shifting MedTech from promise to practice by accelerating R&D (generative design, virtual testing, faster trials and regulatory documentation), optimizing manufacturing, and personalizing commercial and clinical workflows; the FDA has cleared 209 AI-enabled medical devices in 2025 and radiology leads with 956 AI devices approved to date, underscoring regulatory acceptance and incumbent opportunity. The consultancy warns that success hinges on moving from pilots to large-scale implementation as mature technologies and abundant data lower technical barriers while inviting competition from agile startups and tech giants.

Zacks highlights three AI-exposed names: Stryker (SYK) whose Mako SmartRobotics has powered over 2 million procedures with record 2025 installations and Mako 4 expansion; Stryker carries a projected 2025 earnings growth of 11.2%, cashflow rate 12.9% and ROE 24.7%. Tempus (TEM) shows aggressive AI-driven scale—two recent FDA 510(k) clearances, acquisition of Paige (≈7 million annotated slides), projected sales growth of 82.2% and earnings growth of 58.9%; GE HealthCare (GEHC) partners with NVIDIA to shorten scan times and improve imaging, with projected 2025 sales growth of 4.3%, cashflow 9.7% and ROE 22.5%.

Market signals are moderately positive (sentiment score 0.45, market impact 0.35) and Zacks assigns each stock a Rank #3 (Hold), implying upside is execution-dependent. Key risks are execution on scale, data/integration quality, competitive displacement and the pace of additional FDA clearances; investors should track adoption metrics, recurring-revenue conversion and margin expansion as leading indicators.

Key Decisions for Investors

• Allocate selective exposure to Stryker to play durable robotics-driven recurring revenue but monitor Mako installation trends, consumables/service uptake and margin trajectory
• Consider tactical, smaller-weight positions in Tempus to capture high-growth AI upside given projected sales +82.2% and recent FDA clears, while actively monitoring Paige integration and regulatory progress
• Use GE HealthCare for more defensive AI exposure tied to NVIDIA collaboration and product rollouts; watch commercialization of Vivid Pioneer and Pristina Recon DL for revenue inflection
• Monitor cross-company KPIs—number of AI-enabled device approvals, installation/usage metrics, recurring revenue share and cashflow conversion—and be prepared to trim or hedge if adoption stalls
• Respect Zacks’ Hold ratings and the market’s only moderately positive sentiment by employing phased entries or position-sizing limits rather than full conviction buys